Registry update — unassessed
Senolytic Drugs Attenuate Osteoarthritis-Related Articular Cartilage Degeneration: A Clinical Trial
Trial registry update: COMPLETED. Results are posted in the registry; assessment pending.
RCTNotable significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Sep 19, 2024 · Discovered: Sep 16, 2026 · Assessed: — · Historical research backfill
What it does not prove
- No efficacy data are reported in the abstract, so whether fisetin reduces cartilage degeneration or improves joint symptoms cannot be determined.
- Sample size is not provided, preventing assessment of statistical power or whether findings could reflect chance variation.
- Phase I/II trials are preliminary; results do not establish clinically meaningful benefit in large populations.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- —
- Population
- —
- Primary outcome
- Osteoarthritis-related articular cartilage degeneration
- Effect size
- —
- Significance
- Not reported
- Journal
- Steadman Philippon Research Institute
- Published
- Sep 19, 2024
Sources
Primary source
- Steadman Philippon Research Institute ↗Clinical trial
Recorded source passages
Abstract or registry material supplied for assessment; source version 1. This is not a claim of full-text review.
Phase I/II randomized, double-blind, placebo-controlled clinical trial to test the safety and efficacy of Fisetin for treating mild to moderate osteoarthritis
Source versions
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.